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SUMMARY
The Mediator complex relays regulatory signals from gene-specific transcription factors to the basal
transcriptional machinery. However, the role of individual Mediator subunits in different tissues remains
unclear. Here, we demonstrate that MED19 is essential for adipogenesis and maintenance of white adipose
tissue (WAT) by mediating peroxisome proliferator-activated receptor gamma (PPARg) transcriptional activ-
ity. MED19 knockdown blocks white adipogenesis, but not brown adipogenesis or C2C12myoblast differen-
tiation. Adipose-specific MED19 knockout (KO) in mice results in a striking loss of WAT, whitening of brown
fat, hepatic steatosis, and insulin resistance. Inducible adipose-specific MED19 KO in adult animals also re-
sults in lipodystrophy, demonstrating its requirement forWATmaintenance. Global gene expression analysis
reveals induction of genes involved in apoptosis and inflammation and impaired expression of adipose-spe-
cific genes, resulting from decreased PPARg residency on adipocyte gene promoters and reduced associ-
ation of PPARgwith RNA polymerase II. These results identify MED19 as a crucial facilitator of PPARg-medi-
ated gene expression in adipose tissue.
INTRODUCTION
Adipose tissue has emerged as a complex metabolic organ with
a variety of functions. Two major types of adipose tissue are
found in mammals: white adipose tissue (WAT) and brown adi-
pose tissue (BAT). WAT primarily stores energy. In the context
of obesity, WAT dramatically expands to store excess calories,
contributing to metabolic consequences. Alternatively, BAT dis-
sipates energy in the form of heat and is related to positive meta-
bolic outcomes. A subtype of brown fat, called beige fat, can
form in subcutaneous WAT in response to cold exposure and
beta adrenergic signaling. Adipose tissue development is the
result of a complex transcriptional cascade of adipocyte-spe-
cific factors. As the master regulator of adipogenesis, peroxi-
some proliferator-activated receptor gamma (PPARg) plays a
key role in this process, conducting the expression of various
other transcription factors and proteins to ensure that adipocyte
differentiation is completed (Rosen and Spiegelman, 2014).
However, how PPARg regulates the development of two func-
tionally distinct types of adipose tissue as well as the browning
of white fat remains unclear. Previous work in our lab contributed
to this knowledge gap by showing that the peroxisomal lipid syn-
thetic enzyme PexRAP acts as a transcriptional regulator of ad-
ipose tissue gene expression by preventing the interaction of
PPARgwith PRDM16 and inhibiting PRDM16-mediated thermo-
genic gene expression (Lodhi et al., 2017). A global protein-pro-
tein interaction screen indicated that PexRAP (encoded by
Dhrs7b) interacts with the Mediator complex protein MED19
(Stelzl et al., 2005), suggesting the possibility that MED19 could
be involved in adipocyte gene expression.
The Mediator complex is composed of more than 30 subunits
and acts as a bridge between gene-specific transcription factors
and the basal transcription machinery. The subunit composition
of the Mediator can vary, and different subunits interact with
different transcription factors in a cell-context-dependent
manner. Overall, very little is known about the regulation of this
process or the specific function of the individual subunits (Allen
and Taatjes, 2015). Several Mediator components have been
implicated in adipogenesis and adipocyte gene expression
(Zhang et al., 2013). In particular, MED1 is important for white
adipogenesis through interactions with PPARg (Ge et al., 2002,
2008), a process which is facilitated by MED14 (Grøntved
et al., 2010). MED1 also plays a role in brown-fat-specific gene
expression by facilitating recruitment of PRDM16 to the UCP1
enhancer (Chen et al., 2009; Iida et al., 2015). MED23 is neces-
sary for hormone-induced adipogenesis by facilitating the
expression of the early adipogenesis transcription factor
Krox20 (Wang et al., 2009), and it plays a critical role in control-
ling the cell fate preference directing differentiation of smooth
muscle cells or adipocytes (Yin et al., 2012). MED17 is required
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Figure 1. MED19 Is Required forWhite Adipogenesis, andMicewith Adipose-Specific Knockout (KO) ofMED19 Exhibit a Severe Loss ofWAT
and Whitening of BAT
(A) Oil red O staining in differentiated iWAT SVF cells. Scale bar, 300 mm
(B) qPCR analysis of differentiated iWAT SVF cells; n = 3 each.
(C) Oil red O staining in differentiated BAT SVF cells. Scale bar, 300 mm
(D) qPCR analysis of differentiated BAT SVF cells; n = 3 each.
(legend continued on next page)
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for the transcriptional activation of lipogenic genes in response
to insulin (Viscarra et al., 2017). However, little is known about
the function of MED19. In mammals, some studies have impli-
catedMED19 as a facilitator of RE1 silencing transcription factor
(REST)-imposed neuronal gene silencing (Ding et al., 2009), as
well as roles in cancer metastasis (He et al., 2016; Liu et al.,
2019; Wen et al., 2013). We now identify MED19 as a key player
in adipogenesis and maintenance of WAT mass.
RESULTS
MED19 Is Required for White Adipogenesis
To study the role of MED19 in adipogenesis, we treated stromal
vascular fraction (SVF) cells derived from inguinal WAT (iWAT)
with MED19-targeting or scrambled lentiviral short hairpin RNA
(shRNA) and stimulated the cells to differentiate into white adipo-
cytes (Figure 1). MED19 knockdown almost completely blocked
adipogenesis, leading to a striking decrease in lipid droplet
accumulation (Figure 1A), as well as significant decreases in
adipocyte-specificmarkers and transcription factors (Figure 1B).
Surprisingly, Kr€uppel-like factor 5 (KLF5), a zinc-finger transcrip-
tion factor that is involved early in the adipogenic transcription
cascade and critical for WAT development (Oishi et al., 2005),
was increased following MED19 knockdown, suggesting
possible compensation for a downstream transcriptional block.
In support of this, we performed a time course analysis of key
transcriptional events during in vitro adipogenesis in MED19
inducible knockout (KO) iWAT SVF cells (Figure S1A–S1G).
Despite blocking adipogenesis in these cells, MED19 KO had
no effect on or increased the expression of the early adipogenic
transcription factors, such as CCAAT-enhancer-binding protein
beta (C/EBPb), C/EBPd, and KLF5 (Figures S1B–S1D). However,
MED19 KO cells failed to induce PPARg and C/EBPa (Figures
S1E and S1F) or downstream transcriptional targets, such as
CD36 (Figure S1G). These results suggest that MED19 is
required for maintaining C/EBPa and PPARg gene expression
and inactivation of this Mediator protein results in a feedback in-
duction of KLF5, a transcription factor known to link C/EBPb and
C/EBPd to PPARg and C/EBPa in the adipogenic transcription
cascade (Oishi et al., 2005).
To determine if MED19 is a specific mediator of white adipo-
genesis, we also knocked down its expression in SVF cells
derived from BAT of neonatal mice, followed by differentiation
into brown adipocytes. Notably, MED19 knockdown did not
inhibit adipogenesis in brown adipocytes and even led to a sig-
nificant increase in expression of the brown adipocyte genes
(Figures 1C and 1D). Moreover, MED19 knockdown in C2C12
myoblasts did not influence their ability to differentiate into
myotubes (Figures 1E and 1F), suggesting that MED19 plays a
specific role in adipogenesis rather than acting as a general regu-
lator of transcription. Consistent with this notion, previous
studies demonstrate that MED19 deficiency does not affect
the structural integrity of the Mediator complex in yeast or
mammalian cells or cause a gross transcriptional defect
and cell death (Baidoobonso et al., 2007; Ding et al., 2009).
Assessment of cell viability using the WST-1 reagent assay
confirmed thatMED19 knockdown does not affect themetabolic
health of iWAT SVF cells and C2C12 myoblasts (Figures S1H
and S1I).
Generation of Adipose-Specific MED19 KO Mice
To investigate the role of MED19 in adipose tissue, we obtained
mice with a conditional-potential allele of MED19 from the Euro-
pean Conditional Mouse Mutagenesis Program (EUCOMM) re-
pository, crossed themwith actin-Flp transgenic mice to remove
the targeting cassette, and then subsequently crossed the mice
with adiponectin-Cre mice to generate adipose-specific MED19
KO (MED19-AKO) mice (Figures 1G and 1H). The mutant mice
were overtly normal into the early adulthood (8 weeks) and fertile,
at least until 12 weeks of age. Quantitative real-time PCR and
western blot analyses showed that MED19 RNA and protein
were significantly reduced in gonadal WAT (gWAT), iWAT, and
BAT, but not the livers of MED19-AKO mice (Figures 1I and 1J).
MED19-AKO Mice Exhibit a Severe Atrophy of WAT and
Whitening of Brown Fat
Although younger MED19-AKO mice weighed the same as their
control littermates, older male MED19-AKO mice had increased
body weight (Figure 1K), a trend that we saw in female mice as
well (Figure S1J). Food intake was not significantly different be-
tween control and MED19-AKO mice (Figure S1K). Body compo-
sition analysis revealed reduced fat mass but slightly increased
lean mass in both male and female mice (Figures S1L and S1M).
Despite the increased body weight, weights of white fat depots
(gWAT and iWAT) were dramatically reduced in MED19-AKO
mice (Figure 1L), resembling mice with adipose-specific KO of
PPARg (Wang et al., 2013) or insulin receptor (Qiang et al.,
2016), which weigh more than wild-type mice in the context of a
(E) Images of differentiated C2C12 cells stained with DAPI (blue) and myosin heavy chain (MHC) antibody (green) at 503. Scale bar, 100 mm
(F) qPCR analysis of differentiated C2C12 cells; n = 3 each.
(G) Schematic of MED19 gene targeting strategy.
(H) Genotyping of MED19 floxed mice.
(I) qPCR analysis of MED19 expression in adipose tissue depots and liver of MED19-AKO and control animals; n = 5–7.
(J) Western blot analysis using MED19 and actin antibodies in adipose tissue depots.
(K) Body weight of control and MED19-AKO mice at 3 (n = 4 each), 6 (n = 7 Lox/Lox, 10 AKO), 9 (n = 4 Lox/Lox, 5 AKO), and 12 weeks of age (n = 9 Lox/Lox,
20 AKO).
(L) Tissue weight of gWAT, iWAT, BAT, and liver; n = 9 Lox/Lox and n = 10 MED19-AKO mice.
(M) Gross images of iWAT, gWAT, and BAT from Lox/Lox and MED19-AKO mice. Scale bar, 0.5 cm.
(N) H&E staining in iWAT, gWAT, and BAT. Scale bar, 75 mm.
(O) qPCR analysis of gWAT; n = 6 Lox/Lox and n = 5 MED19-AKO.
(P) qPCR analysis of BAT; n = 5 Lox/Lox and n = 7 MED19-AKO.
*p < 0.05, **p < 0.005, and ***p < 0.0005. For all panels, the error bars represent the SEM. See also Figure S1.
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dramatic reduction in adipose tissuemass.Other smallerWATde-
pots, such as anterior subcutaneous WAT (asWAT), retroperito-
neal WAT (rWAT), and mesenteric WAT (mWAT), were also
reduced in MED19-AKO mice (Figure S1N). Liver weight was
markedly increased in MED19-AKO mice (Figure 1L), explaining
their elevated body weight. In contrast to the striking loss of
WAT, MED19-AKO mice had no change in BAT mass (Figure 1L).
We also determined the effect of MED19 inactivation on adipose
tissue of youngmice at3 weeks of age, when they are undergo-
ing a rapid growth of adipose tissue. Interestingly, the young
MED19-AKO mice also showed a significant reduction in gWAT
and iWAT mass but no change in BAT mass, suggesting that
MED19 might play a role early on in WAT development (Fig-
ure S1O). In adult mice, gross examination revealed that the inter-
scapular BAT of KO animals was much paler, resembling WAT
(Figure 1M). The small amount of remaining white fat in MED19-
AKO animals appeared unhealthy in histological sections,
showing sparse, irregularly sized adipocytes among a fibrous
extracellular matrix, and while brown fat contained many white-
adipocyte-like unilocular cells (Figure 1N). Gene expression anal-
ysis of gWAT and iWAT from MED19-AKO animals showed
decreased levels of the adipocyte genes aP2, C/EBPa, and
PPARg (Figures 1O and S1P). Consistent with the in vitro results,
C/EBPb and KLF5 expression was either unchanged or elevated
in MED19-AKO animals, suggesting that MED19 may play a role
downstream of these factors in the adipogenic transcription
cascade. The expression of BAT genes, including UCP1, was
also decreased in MED19-AKO mice (Figure 1P).
MED19-AKO Mice Exhibit Fatty Liver and Insulin
Resistance
Given the decreased adiposity and increased liver weight, we
next examined whether MED19-AKO mice exhibit hepatic stea-
tosis and insulin resistance (Figure 2). Upon gross examination,
livers of 12-week-old MED19-AKO animals were enlarged and
pale (Figure 2A). Histological examination showed a massive
accumulation of lipid droplets (Figure 2A) and 4-fold higher tri-
glyceride content in the livers of MED19-AKO mice (Figure 2B).
Assessment of glucose homeostasis revealed that both male
and female MED19-AKO mice were hyperglycemic and glucose
intolerant (Figures 2C and S2). Moreover, MED19-AKOmice dis-
played an impaired response to insulin in an insulin tolerance test
(Figure 2D), as well as elevated fasting serum insulin levels (Fig-
ure 2E). KO mice had impaired hepatic insulin signaling, as as-
sessed by phosphorylation of Akt in response to insulin (Figures
2F and 2G).
Figure 2. MED19-AKO Mice Have Fatty Liver and Insulin Resistance
(A) Gross and histological images of H&E-stained liver. Scale bars represent 0.5 cm (gross liver images) and 75 mm (liver histology).
(B) Liver triglyceride content; n = 8 Lox/Lox mice and n = 11 MED19-AKO mice.
(C) Glucose tolerance test; n = 20 Lox/Lox mice and n = 13 MED19-AKO mice.
(D) Insulin tolerance test; n = 7 each.
(E) Serum insulin ELISA; n = 4 Lox/Lox mice and n = 5 MED19-AKO mice.
(F) Western blot analysis of Akt phosphorylation in livers of MED19-AKO and control mice at baseline and 10 min following insulin injection.
(G) Quantification of the results in (F); n = 4 each.
*p < 0.05, **p < 0.005, and ***p < 0.0005. For all panels, the error bars represent the SEM. See also Figure S2.
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Deletion of MED19 in Mature Adipose Tissue Causes
Lipodystrophy due to Increased Apoptosis and
Macrophage Infiltration
To investigate the role of MED19 in mature adipose tissue, we
created an adipose-specific, tamoxifen-inducible MED19 KO
(MED19-iAKO) mouse line (Figure 3A). MED19-iAKO and Lox/
Lox control mice were injected with tamoxifen for 5 consecutive
days to induce the activity of the adiponectin-CreER fusion pro-
tein, resulting in KO of the gene in adipose tissue depots (Fig-
ure 3B). Twenty-one days later, MED19-iAKO mice had no
change in body weight (Figure S3A) but showed a dramatic
reduction in gWAT and iWAT mass (Figures 3C and 3D). Histo-
logic analysis of the residual white fat in MED19-iAKO mice
demonstrated a markedly decreased number of irregularly sized
adipocytes, while BAT exhibited whitening, as indicated by
accumulation of unilocular lipid droplets (Figure 3E). Oil red O
staining confirmed that the pockets of white-adipocyte-like cells
within BAT of MED19-iAKO were in fact adipocytes (Figure 3E).
We next sought to understand the mechanism underlying the
dramatic loss of WAT following acute inactivation of MED19
in adult animals. To determine if increased lipolysis was respon-
sible, we measured glycerol release from adipose tissue explants
in the presence or absence of isoproterenol. Surprisingly, iWAT
from MED19-iAKO mice displayed impaired lipolytic activity (Fig-
ure S3B), likely due to decreased gene expression of factors
involved in lipolysis, including adipose triglyceride lipase (ATGL),
hormone-sensitive lipase (HSL), and Abhd5 (Figure S3C).
Next, we determined whether MED19 inactivation promotes
apoptosis inWAT.Western blot analysis and immunohistochem-
istry staining of cleaved caspase-3 indicated an accumulation of
apoptotic cells in the iWAT of MED19-iAKO animals (Figures 3F
and 3G). Consistent with increased adipose tissue inflammation
and death, we observed significant macrophage infiltration in the
gWAT and iWAT of MED19-iAKO mice as measured by F4/80
immunofluorescence analysis (Figures 3H and 3I).
MED19 Maintains Adipocyte Gene Expression by
Facilitating PPARg-Mediated Gene Expression
To gain a better understanding of howMED19 regulates the tran-
scriptional landscape in adipose tissue, we performed RNA
sequencing (RNA-seq) on gWAT of MED19-iAKO mice 14 days
after tamoxifen injection (Figure 4A), followed by Kyoto Encyclo-
pedia of Genes andGenomes (KEGG) pathway analysis of genes
that were significantly up- or downregulated in MED19-iAKO an-
imals compared to controls (Figure 4B). Induced genes estab-
lished a clear pattern of almost exclusively being involved in
pathways associated with cell death, inflammation, and inflam-
matory cell signaling/recruitment (Figure 4B). This analysis sup-
ports the hypothesis that MED19 KO inWAT leads to lipoatrophy
via cell death and inflammation. KEGG pathway enrichment
analysis for downregulated genes identified pathways important
in both adipocyte-specific metabolism and signaling (Figure 4B).
In particular, genes involved in the PPAR signaling pathway were
significantly downregulated in MED19-iAKO adipose tissue,
suggesting that MED19 may be involved in facilitating PPARg-
mediated gene expression. In order to determine transcriptional
circuits facilitated by MED19, we applied the dataset of downre-
gulated genes identified in RNA-seq (false discovery rate [FDR]
<0.05) to Hypergeometric Optimization of Motif EnRichment
(HOMER) analysis (Heinz et al., 2010), which found an enrich-
ment of DNA-bindingmotifs for PPARg, C/EBP transcription fac-
tors, and KLF4 (Figure 4C).
Given these findings and the similarities between our mice and
those with adipose-specific deletion of PPARg (Wang et al.,
2013), we sought to determine whether MED19 interacts with
PPARg. Glutathione S-transferase (GST) pull-down assay
indicated that MED19 interacts with FLAG-tagged PPARg (Fig-
ure 4D). To investigate the effects of MED19 on PPARg-
mediated gene expression, we created a reporter assay by
stably transfecting tamoxifen-inducible MED19 KO (MED19-
iKO) iWAT SVF cell line with a PPARg-dependent luciferase
reporter along with PPARg and RXRa. MED19 KO significantly
blunted the ability of cells to activate the reporter at both baseline
and in response to the PPARg agonist rosiglitazone (Figure 4E),
despite a lack of difference in PPARg expression between con-
trol andMED19-KO cells (Figure 4F). To determine whether dele-
tion of MED19 in adipocytes leads to decreased occupancy of
PPARg at PPARg response elements (PPREs) of target genes,
we performed chromatin immunoprecipitation (ChIP) assays us-
ing an antibody against PPARg in adipocytes subjected to acute
tamoxifen-inducible KO of MED19. Consistent with the result of
the PPARg reporter assay, ChIP-qPCR analysis of PPARg bind-
ing to known PPREs (Lefterova et al., 2010; Rajakumari et al.,
2013; Villanueva et al., 2011) was significantly reduced in
MED19-KO cells (Figure 4G), resulting in decreased gene
expression of PPARg-dependent genes (Figure 4H).
Next, we determined whether overexpression of PPARg alone
or together with C/EBPa could rescue the effect of MED19 inac-
tivation of adipogenesis. Interestingly, ectopic expression of
PPARg or PPARg and C/EBPa in conjunction with rosiglitazone
could not recue the adipogenesis defect in MED19-depleted
cells (Figures S4A–S4E). Because the Mediator complex relays
signals from upstream signaling pathways to the basal transcrip-
tional machinery, we next determined whether MED19 links
PPARg to RNA polymerase II (RNA Pol II). To this end, we per-
formed proximity ligation assay (PLA) (Figure 4I) under condi-
tions identical to those used in the ChIP assay (Figure 4G). The
results of the PLA assay indicate that KO of MED19 in iWAT
SVF cells treated with adipogenic cocktail greatly reduces the
association of PPARg with RNA Pol II to levels similar to those
in undifferentiated cells (Figures 4J and 4K), despite a lack of dif-
ference in PPARg expression (Figure S4F). It is noteworthy that
while sustainedMED19 inactivation inmice or iWAT SVF cells re-
sults in decreased PPARg gene expression, acute tamoxifen-
inducible KO of the Mediator protein during adipogenesis in
iWAT SVF cells as performed here did not impair PPARg gene
expression, thus allowing assessment of the effect on PPARg
transcriptional activity. Together, these results suggest that
MED19 is necessary for the formation of an RNA Pol II/PPARg
adipogenic transcription complex and themaintenance of down-
streamPPARg signaling required for adipocyte gene expression.
DISCUSSION
The Mediator is a multi-subunit complex that acts as a bridge
between gene-specific transcription factors and the basal
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transcription machinery. MED19 is a poorly characterized Medi-
ator subunit, but previous studies indicate that MED19 mutant
yeast strains are viable, with no impairment of the global tran-
scriptional program (Dettmann et al., 2010). Moreover, deletion
of MED19 does not disrupt the structural integrity or function
of the Mediator complex in both yeast (Baidoobonso et al.,
Figure 3. Tamoxifen-Inducible KO of MED19 in Mature Adipose Tissue Causes Loss of WAT due to Increased Apoptosis and Macrophage
Infiltration
(A) Schematic of tamoxifen-inducible, adipose-specific MED19 KO.
(B) qPCR analysis of MED19 expression in adipose and liver of MED19-iAKO and control mice; n = 4–5 each.
(C) Gross images of iWAT, gWAT, and BAT from MED19-iAKO and control mice. Scale bar, 0.5 cm.
(D) Tissue weights of MED19-iAKO and control mice normalized to body weight; n = 5 each.
(E) Histology images of iWAT, gWAT, and BAT from MED19-iAKO and control mice. Scale bar, 300 mm.
(F) Staining of iWAT tissue with cleaved caspase-3 antibody. Scale bar, 75 mm.
(G) Western blot analysis of cleaved caspace-3 in iWAT.
(H) Wholemounts of iWAT from control andMED19-iAKOmice 10 days after tamoxifen injections were stained with F4/80 (red), LipidTox (green), and DAPI (blue).
Scale bar, 100 mm.
(I) Quantification of F4/80 staining from (H).
**p < 0.005 and ***p < 0.0005. For all panels, the error bars represent the SEM. See also Figure S3.
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Figure 4. MED19 Maintains Adipocyte Gene Expression by Facilitating PPARg-Mediated Gene Expression
(A) Volcano plot of RNA-seq analysis in gWAT of 12-week-old MED19-iAKO and control mice 14 days after tamoxifen injections.
(B) Top 15 KEGG pathways identified in FDR-corrected, up-/downregulated gene expression subsets.
(C) HOMER analysis on FDR-corrected, downregulated genes. p values represent enrichment of indicated binding motif.
(D) FLAG-PPARg2 pull-down using GST-tagged MED19.
(E) PPARg-dependent luciferase reporter activity in MED19-iKO iWAT SVF cells transfected with pLJM1-PPRE-TK-Luc, pBABE-RXRa, and pLJM1-FLAG-
PPARg2 and treated with vehicle or 1 mM 4-hydroxy-tamoxifen (4OH TAM) for 2 days; n = 3.
(F) Gene expression analysis of the cells from (E); n = 3 each.
(G) MED19-iAKO iWAT SVF cells were differentiated and treated with vehicle or 4-OH TAM before being harvested. ChIP was performed using an anti-PPARg
antibody, followed by qPCR using primers for the indicated genes. Results are background corrected to a normal immunoglobulin G (IgG) control and expressed
as percent input; n = 3 each.
(H) Gene expression analysis by qPCR; n = 3 each.
(I) Schematic of the proximity ligation assay (PLA).
(J) Colocalization of PPARgwith RNAPol II as determined by PLA in iWATSVF cells after treatment with adipogenic cocktail. Red, PLA-positive signal; blue, DAPI.
Scale bar, 75 mm.
(K) Quantification of the results from (J).
*p < 0.05, **p < 0.005, and ***p < 0.0005. For all panels, the error bars represent the SEM. See also Figure S4.
Cell Reports 33, 108228, October 6, 2020 7
Report
ll
OPEN ACCESS
2007) and HeLa cells (Ding et al., 2009). Given these findings,
MED19 is a subunit that likely harbors more nuanced functions.
Here, we provide evidence suggesting that MED19 is essential
for adipogenesis and maintenance of WATmass. Knockdown of
MED19 in iWAT SVF cells, but not C2C12 myoblasts, blocks dif-
ferentiation, indicating a cell-specific role in adipogenesis. It is
noteworthy that another Mediator subunit, MED23, is also
dispensable for myoblast differentiation but important for hor-
mone-induced adipogenesis in mouse embryonic fibroblasts
by facilitating the activity of Elk1 early on in the adipogenic tran-
scription cascade (Wang et al., 2009). As MED19 knockdown in
iWAT SVF cells prevented induction of downstream adipogenic
genes such as aP2 and C/EBPa but had a little to no effect on
the expression of upstream genes such as C/EBPb and KLF5,
we hypothesized that MED19 is involved in the early stages of
adipogenesis, similar to the role of MED23. However, unlike
MED23, the block in adipogenesis due to MED19 inactivation
could not be rescued by overexpression of C/EBPa and/or
PPARg (Figure S4). This suggests that MED19 plays a direct
role in facilitating PPARg activity rather than promoting PPARg
induction, since PPARg overexpression and agonism has been
shown to not only be sufficient for adipogenesis but also rescue
upstream blocks in adipogenesis in vitro (Rosen et al., 2002;
Tontonoz et al., 1994; Wang et al., 2009; Zuo et al., 2006).
In mice, adipose-specific deletion of MED19 resulted in
near-ablation of WAT, leading to hepatic steatosis and insulin
resistance. BAT mass was unaffected, but MED19-AKO mice
manifested a significant whitening of the thermogenic fat.
Although many genetic KO mouse models have been reported
to have lipodystrophic phenotypes (Rochford, 2014; Savage,
2009), it is unusual to see such a severe defect in WAT that is
not also seen in BAT. Of note, mice with a heterozygous KO
for KLF5 (KLF+/) show significant defects in neonatal WAT
development but exhibit no difference in interscapular BAT
mass compared to wild-type littermates (Oishi et al., 2005). Simi-
larly, C/EBPa null mice rescued by transgenic hepatic expres-
sion have an absence of WAT, with no defects in BAT outside
of mild adipocyte hypertrophy (Linhart et al., 2001). Thus, it is
possible that MED19 is part of a transcription regulatory network
that includes C/EBPa and KLF5.
To understand the cell-intrinsic role of MED19 in brown adipo-
cytes, we knocked down its expression in SVF cells derived from
BAT of neonatal mice. Surprisingly, the knockdown did not block
brown adipogenesis and in fact significantly increased brown
adipocyte gene expression. The inability of MED19 knockdown
to block brown adipocyte differentiation supports the possibility
that MED19 does not affect BAT development in mice. However,
the effect of MED19 knockdown on gene expression in neonatal
brown adipocytes is in contrast to the decreased PPARg and
UCP1 gene expression in BAT of adult MED19 KO mice. It is
possible that MED19 is not necessary for BAT development and
may even inhibit thermogenic gene expression in neonatal mice
but is later required to maintain BAT gene expression as mice
get older. Similarly, PRDM16 is dispensable for embryonic devel-
opment of BAT but is required for maintenance of brown adipo-
cyte identity and function in adult animals (Harms et al., 2014).
Adipose-specific MED19 KO in adult animals suggests that
this factor is critical for maintenance of WAT mass. RNA-seq
analysis of MED19-iAKO gWAT revealed upregulation of genes
involved in apoptosis, necroptosis, and inflammation and down-
regulation of PPARg-dependent genes. WAT in MED19-iAKO
animals showed a marked increase in macrophage infiltration
and accumulation of apoptotic cells, a phenotype very similar
to that of mice with adipose-specific deletion of PPARg (Wang
et al., 2013). These data suggest that MED19 is necessary for
mediating PPARg transcriptional activity. HOMER analysis of
our RNA-seq dataset revealed that downregulated genes in
MED19-AKO adipose tissue had enrichment of PPARg binding
motifs, further implicating MED19 in PPARg signaling. In support
of this possibility, MED19-iKO iWAT SVF cells showed reduced
residency of PPARg on adipose-specific target genes and blunt-
ed PPARg luciferase reporter activity.
In summary, our studies identify MED19 as a crucial facilitator
of PPARg-mediated gene expression that is required for adipo-
genesis and maintenance of WAT mass. Future studies aimed
at understanding precisely how MED19 links signals from
PPARg to the basal transcriptional machinery to preferentially
control white fat levels could identify a novel therapeutic strategy
for treating obesity.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal Anti-FLAG M2 MilliporeSigma F1804; RRID: AB_262044
Rabbit polyclonal anti-Actin Santa Cruz Biotechnology SC-1616-R; RRID: N/A
Mouse monoclonal anti-RNA polymerase II MilliporeSigma 05-623; RRID: AB_309852
Rabbit polyclonal anti-HA Santa Cruz Biotechnology sc-805; RRID: AB_631618
Rabbit polyclonal anti-Phospho-Akt (Ser473) Cell Signaling Technology 9271; RRID: AB_329825
Rabbit polyclonal anti-AKT Cell Signaling Technology 9272; RRID: AB_329827
Rabbit monoclonal anti-PPARg (81B8) Cell Signaling Technology 2443S; RRID: AB_823598
Rabbit polyclonal anti-MED19 Invitrogen PA5-44383; RRID: AB_2610610
Rabbit polyclonal anti-Cleaved Caspase-3 (Asp175) Cell Signaling Technology 9661; RRID: AB_2341188
Mouse monoclonal anti-MHC Developmental Studies
Hybridoma Bank
MF20; RRID: AB_1293549
Alexa Fluor 647 anti-mouse F4/80 Antibody Biolegend 123121; RRID: AB_893492
Peroxidase IgG Fraction Monoclonal Mouse
Anti-Rabbit IgG, light chain specific
Jackson Immunoresearch 211-032-171; RRID: AB_2339149
Peroxidase AffiniPure Goat Anti-Mouse IgG, light
chain specific
Jackson Immunoresearch 115-035-174; RRID: AB_2338512
Mouse monoclonal anti-RNA Polymerase II MilliporeSigma 05-623; RRID: AB_309852
Bacterial and Virus Strains
E. coli: Stable competent NEB C3040I
E.coli: DH5a competent cells Thermo Fisher Scientific 18265017
Biological Samples
Fetal Bovine Serum GIBCO 26140-079
Horse Serum Thermo Fisher Scientific 16050122
Chemicals, Peptides, and Recombinant Proteins
Cell Proliferation Reagent WST-1 Roche 5015944001
Insulin (IP injections) Lilly Humalin, R
Vectashield mounting medium Vector Labs H-1000
DMEM high glucose MilliporeSigma D6429
DMEM F-12 Ham MilliporeSigma D6421
Tamoxifen MilliporeSigma T5648
Corn Oil MilliporeSigma C8267
4-hydroxy-tamoxifen MilliporeSigma H-6278
Dexamethasone MilliporeSigma D-1756
Insulin MilliporeSigma I-5523
Rosiglitazone Cayman Chemical 71740
3-Isobutyl-1-methylxanthine MilliporeSigma I5879
Collagenase D Roche 11088866001
Dispase II MilliporeSigma D4693
Ampicillin GoldBio A-301-5
Penicillin-Streptomycin GIBCO 15140-122
0.05% Trypsin-EDTA GIBCO 25300-054
Triton X-100 MilliporeSigma T8787
Lipofectamine 2000 Reagent Invitrogen 11668-027
HCS LipidTox Invitrogen H34475
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REAGENT or RESOURCE SOURCE IDENTIFIER
PowerUP SYBR Green Master Mix Applied Biosystems A25742
TRIzol reagent Invitrogen 15596026
SuperSignal West Femto Maximum Sensitivity Substrate Thermo Fisher Scientific 34096
Protease inhibitor MilliporeSigma P8340
DAPI MilliporeSigma 10236276001
Precision Plus Protein Kaleidoscope Prestained Protein
Standards
Bio-Rad 1610375
Protein A/G PLUS-Agarose beads Santa Cruz Sc-2003
Critical Commercial Assays
Duolink In Situ Red Starter Kit Mouse/Rabbit MilliporeSigma DUO92101
SimpleChIP Plus Enzymatic Chromatin IP Kit Cell Signaling Technology 9004
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 23225
Ultra Sensitive Mouse Insulin ELISA kit Crystal Chem 90080
Lipolysis Colorimetric Assay Kit MilliporeSigma MAK211
Vectastain Universal Elite ABC kit Vector Labs PK-6200
Luciferase Assay System kit Promega E1500
High-Capacity cDNA Reverse Transcription kit Applied Biosystems 4368814
PureLink RNA mini kit Invitrogen 12183018A
Deposited Data
MED19-iAKO gWAT RNA-seq data This paper GSE150250
Experimental Models: Cell Lines
C2C12 ATCC CRL-1772
HEK293T ATCC CRL3216
iWAT SVF cells Lodhi et al., 2017 N/A
BAT SVF cells Lodhi et al., 2017 N/A
PPARg-MEFs Lodhi et al., 2017 N/A
MED19 iWAT SVF cells This paper N/A
MED19-iKO This paper N/A
Experimental Models: Organisms/Strains
Mouse: MED19-AKO This paper N/A
Mouse: MED19-iAKO This paper N/A
Mouse: Adiponectin Cre The Jackson Laboratory 028020
Mouse: Adiponectin CreERT2 The Jackson Laboratory 025124
Oligonucleotides
See Table S1 for oligonucleotide sequences This paper
Recombinant DNA
psPAX2 Addgene #12260
pMD2.G Addgene #12259
Scramble shRNA Addgene #1864
pLJM1-EGFP Addgene #19319
PPRE X3-TK-luc Addgene #1015
pBABE puro PPAR gamma 2 Addgene #8859
MED19 lentivirus shRNA MilliporeSigma TRCN000258189
MSCV CreERT2 puro Addgene #22776
pBABE-neo largeTcDNA Addgene #1780
pLJM1-PPRE X3-TK-luc This paper N/A
pLJM1-FLAG-PPARg This paper N/A
pBABE puro human RXR alpha Addgene #11441
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Irfan J.
Lodhi (ilodhi@wustl.edu).
Materials Availability
The unique cell lines andmouse models generated in this study are available from the Lead Contact, Irfan J. Lodhi (ilodhi@wustl.edu)
upon completion of a materials transfer agreement.
Data and Code Availability
The MED19-iAKO gWAT RNA-sequencing data have been deposited in the GEO repository and can be accessed with accession
code GSE150250
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
To create MED19-AKO mice, we obtained mice with conditional-potential allele of MED19 (MED19tm1a(EUCOMM)Wtsi from the
EUCOMM repository and crossed them with actin-Flp transgenic mice to remove the targeting cassette and then subsequently
crossed the mice with adiponectin-Cre mice obtained from the Jackson Laboratory (028020) to generate adipose-specific
MED19 knockout (MED19-AKO) mice. To generate adipose-specific, tamoxifen-inducible MED19 KO (MED19-iAKO) mice,
MED19 floxed animals were crossed with Adiponectin-CreER mice obtained from the Jackson Laboratory (025124). To induce
knockout, 12-week-od control (MED19Lox/Lox without Cre) and MED19- iAKO mice were treated daily with tamoxifen (100 mg/g
body weight) for five consecutive days. All experiments used male mice unless otherwise stated. All mice were kept on a 12h
light/dark cycle and provided ad libitum access to food (Purina 5053) and water. All animal experiments were performed in accor-
dance with procedures approved by the Institutional Animal Care and Use Committee at Washington University School of Medicine.
Cell Lines
Stromal vascular fraction cells from adult iWAT and postnatal day 1 interscapular BAT were isolated from wild-type C57 mice by
collagenase and dispase digestion, immortalized, and differentiated into adipocytes as previously reported (Lodhi et al., 2017;
Park et al., 2019). Inducible MED19 KO iWAT SV cells (MED19-iKO) were generated by treating iWAT SVF cells obtained from
MED19Lox/Lox animals withMSCVCreERT2 puro retrovirus (Addgene #22776). C2C12 cells weremaintained in DMEMsupplemented
with 10% FBS. To induce differentiation, C2C12 cells at 80% confluence were switched to DMEM containing 2% horse serum.
Human embryonic kidney 293T (HEK293T) cells were maintained in DMEM supplemented with 10% FBS. Cell viability was assessed
by colorimetric assay using Cell Proliferation Reagent WST-1 (Roche).
METHOD DETAILS
Plasmid Constructs
Plasmid encoding lentivirus shRNA for mouse MED19 (TRCN000258189) was obtained from Sigma-Aldrich (St. Louis, MO). Pack-
aging vector psPAX2 (12260), envelope vector pMD2.G (12259), and scrambled shRNA plasmid (1864) were obtained fromAddgene.
PPRE-TK- luc lentiviral reporter plasmid was generated by replacing the CMV-eGFP insert in pLJM1-eGFP with PPRE-TK-luciferase
from the PPRE X3-TK-luc plasmid (Addgene #1015). Similarly, the pLJM1-FLAG-PPARg was created by cloning FLAG-tagged
PPARg in place of eGFP in the pLJM1-eGFP vector.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
pLJM1-FLAG C/EBP alpha This paper N/A
pcDNA-Myc PPARg This paper N/A
pGEX-4T-1-MED19 This paper N/A
Software and Algorithms
Prism 8 GraphPad https://www.graphpad.com
ImageJ ImageJ https://imagej.nih.gov/ij/
HOMER Heinz et al., 2010 http://homer.ucsd.edu/homer/ngs/index.html
Image Studio LI-COR Biosciences https://www.licor.com/bio/image-studio/
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Immunohistochemistry and Immunofluorescence Imaging
For C2C12 cell immunofluorescence imaging, cells were fixed using ice-cold methanol at 20C for 10 min and permeabilized with
0.1% Triton X-100 in PBS (PBS-T). Cells were incubated with primary MYH1 anti-mouse (DSHB MF20) antibody at 1:100 dilution in
PBS-T at 4C overnight. Alexa Fluor conjugated secondary antibody (Invitrogen A-11008) was used at a dilution of 1:500 at room
temperature for 1 hr. For IHC detection of cleaved caspase-3, formalin-fixed, paraffin-embedded adipose tissue sections were
de-paraffinized and incubated with anti-cleaved caspase-3 antibody (Cell Signaling Technology D175) followed by detection using
the Vectastain Universal Elite ABC kit (Vector Labs) before being mounted and imaged with a Leica DMI4000B fluorescence micro-
scope. Immunofluorescent imaging of whole adipose tissue was done as previously described (Berry et al., 2014). Briefly, freshly
harvested adipose tissue was washed with PBS before being incubated with Alexa fluor 647-conjugated rat anti-mouse F4/80
antibody (Biolegend 123121) at 1:100 overnight, HCS LipidTox (Invitrogen H34475) at 1:100 for 1hr, and DAPI (Invitrogen D1306)
at 1:10,000 for 1hr. After antibody incubation, tissue was washed and mounted using Vectashield mounting medium (Vector
Laboratories H-1000) and imaged Nikon A1Rsi Confocal Microscope. Quantification was performed using ImageJ software. For
oil red O staining, tissue was harvested and transferred to a 4% paraformaldehyde solution overnight. The tissue was subsequently
incubated overnight in a 15% sucrose solution and again in a 30% sucrose solution before being embedded in OCT compound and
put in20C overnight and sectioned. Slides are then dipped in 10% formalin for 10 mins, 60% isopropanol once, Oil Red O solution
for 15mins, 60% isopropanol once, and then DI water 10x before mounting coverslips and imaging.
PPRE Luciferase Assay
MED19-iKO iWAT SVF cells were transduced with both pLJM1-FLAG-PPARg, pBABE-RXR alpha, and pLJM1-PPRE-TK-Luciferase
reporter plasmid lenti-/retroviruses. Cells were treated with media containing vehicle or 4-hydroxytamoxifen for 2 days. Cells were
harvested and luminescencewasmeasured using a Luciferase Assay System kit (Promega E1500). Luminescencewas normalized to
cellular protein as measured by Pierce BCA Assay kit (Thermo Fisher 23227).
RT-qPCR
Total RNA was isolated using TRIzol reagent (Invitrogen 15596026) or PureLink RNA Mini Kit (Invitrogen 12183018A). 2mg of isolated
RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems 4368814). qPCR was per-
formed with a StepOnePlus Real-Time PCR System (Applied Biosystems) using PowerUP SYBR Green Master Mix (Applied Bio-
systems A25742). Assays were performed in duplicate and normalized to ribosomal protein L32.
Insulin ELISA and Insulin Signaling Assay
Serum was collected from 16-week old MED19-AKOmales and insulin concentration was measured using an Ultra Sensitive Mouse
Insulin ELISA kit (Crystal Chem 90080) according to the manufacturer’s suggested protocol. To measure insulin signaling in the liver,
mice were fasted for 4-6 hr before tissue was collected and snap frozen in liquid nitrogen at the basal state or 10 mins after an IP
injection of 5mU/g of insulin (Humulin R, Lilly). Tissue was placed in tissue lysis buffer (0.1% SDS, 0.1% sodium deoxycholate,
1% Triton X-100, 50mM Tris-HCL pH 7.6, 5mM EDTA, 150mM NaCl, 5mM NaF, and protease inhibitor) and homogenized (Glas-Col
099C-K54).
Ex vivo Lipolysis Assay
Ex vivo lipolysis assay was performed using the Lipolysis Colorimetric Assay Kit (Sigma, MAK211) according to the manufacturer’s in-
structions.Briefly, iWAT fromcontrol andMED19-iAKOmicewasharvested,minced, and50mgof tissuewascultured in24-well plates
overnight in DMEM F-12 containing insulin and dexamethasone. Tissue was washed 2x with adipocyte wash buffer and incubated in
lipolysis buffer with or without 100 nM isoproterenol for 1.5 hr before measuring the amount of glycerol in the media using the assay kit.
Chromatin Immunoprecipitation
ChIP studies were conducted using the SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling Technology) according to manufac-
turer’s instruction and as previously described (Lodhi et al., 2017). Briefly, MED19-iKO iWAT SVF cells were treated with differenti-
ation media for 2 days before being switched to maintenance media with or without 4-hydroxy-tamoxifen for 2 days before being
harvested. Cells were fixed with 1% formaldehyde for 15 min. Nuclei were harvested and chromatin digested by micrococcal
nuclease before being lysed on ice by 3 sets of 10 s pulses from a Sonics VCX 500 probe sonicator at 30% amplitude. Chromatin
was clarified by centrifugation before being incubated with normal rabbit IgG or rabbit anti-PPARg (Cell Signaling Technology
81B8) antibodies at 4C overnight. ChIP-Grade protein G agarose beads were incubated for 4 h, spun, and washed. Crosslinks
were reversed and DNA was purified by spin column. DNA was quantified by qPCR using PowerUp Sybr Green Master Mix (Thermo
Fisher) in triplicate and data are shown as percentage of input. Primer sequences used in qPCR are as described previously (Left-
erova et al., 2010; Rajakumari et al., 2013; Villanueva et al., 2011) and full sequences can be found in Table S1.
Proximity Ligation Assay
Proximity ligation assays were performed using Duolink reagents (Sigma) according to the manufacturer’s instructions with PPARg
(Cell Signaling 81B8) and RNA PolII (Sigma-Aldrich 05-623) primary antibodies. MED19-iKO iWAT SV cells were grown on chamber
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slides (Lab-Tek 177445) and differentiated into adipocytes by treating confluent cells with DMEM/F12 supplemented with 5mg/ml
insulin, 0.25 mM Dexamethasone, 1mM rosiglitazone, and 0.5 mM isobutylmethylxanthine. After two days, the cells were switched
to medium supplemented with only 1mM rosiglitazone and 5mg/ml insulin with or without 1mM 4-OHT for two days. Cells were
then fixed with 4% paraformaldehyde (w/v) for 40 min and permeabilized with 0.5% (w/v) Triton X-100 in PBS for 15 min before being
used in PLA assays.
GST Pull-down Assays
For GST pull-downs, cells were lysed using a buffer containing 50 mM HEPES (pH 7.4), 4 mM EDTA, 2 mM EGTA, 2 mM sodium
pyrophosphate, 1% Triton X-100, 10 mM NaF, and protease inhibitors (P8340; Sigma-Aldrich) by rocking in the cold room for
15 mins followed by homogenization using a dounce homogenizer. Cell lysates were clarified by spinning down at 10,000 g for
10 mins and supernatant was mixed with an equal volume of the same buffer containing no Triton X-100, then 5 mg of GST alone
beads or GST fusion protein beads and rocked at 4C for overnight. Samples were spun down at 2,500 g for 5 min and washed
five times with lysis buffer containing 0.5% Triton X-100 before being resuspended in SDS sample buffer and subjected to
SDS-PAGE.
RNA-sequencing and Analysis
gWAT was collected from 12 to 13-week-old female control or Med19-iAKO mice 14 days post tamoxifen injections. RNA was har-
vested using a combination of TRIzol reagent (Invitrogen 15596026) and PureLink RNA Mini Kit (Invitrogen 12183018A) before being
submitted to the Genome Technology Access Center (GTAC) at Washington University School of Medicine in St. Louis for RNA
sequencing and analysis.
Samples were prepared according to library kit manufacturer’s protocol, indexed, pooled, and sequenced on an Illumina HiSeq.
Basecalls and demultiplexing were performed with Illumina’s bcl2fastq software and a custom python demultiplexing programwith a
maximum of onemismatch in the indexing read. RNA-seq reads were then aligned to the Ensembl release 76 top-level assembly with
STAR version 2.0.4b (Dobin et al., 2013). Gene counts were derived from the number of uniquely aligned unambiguous reads by Sub-
read:featureCount version 1.4.5 (Liao et al., 2014). Isoform expression of known Ensembl transcripts were estimated with Sailfish
version 0.6.13 (Patro et al., 2017). Sequencing performance was assessed for the total number of aligned reads, total number of
uniquely aligned reads, and features detected. The ribosomal fraction, known junction saturation, and read distribution over known
gene models were quantified with RSeQC version 2.3 (Wang et al., 2012).
All gene counts were then imported into the R/Bioconductor package EdgeR (Robinson et al., 2010) and TMM normalization size
factors were calculated to adjust for samples for differences in library size. Ribosomal genes and genes not expressed in the
smallest group sizeminus one samples greater than one count-per-million were excluded from further analysis. The TMM size factors
and the matrix of counts were then imported into the R/Bioconductor package Limma (Ritchie et al., 2015). Weighted likelihoods
based on the observed mean-variance relationship of every gene and sample were then calculated for all samples with the
voomWithQualityWeights (Liu et al., 2015). The performance of all genes was assessed with plots of the residual standard deviation
of every gene to their average log-count with a robustly fitted trend line of the residuals. Differential expression analysis was then
performed to analyze for differences between conditions and the results were filtered for only those genes with Benjamini-Hochberg
false-discovery rate adjusted p values less than or equal to 0.05.
For each contrast extracted with Limma, global perturbations in known Gene Ontology (GO) terms and KEGG pathways were
detected using the R/Bioconductor package GAGE (Luo et al., 2009) to test for changes in expression of the reported log 2 fold-
changes reported by Limma in each term versus the background log 2 fold-changes of all genes found outside the respective
term. The R/Bioconductor package heatmap3 (Zhao et al., 2014) and Pathview (Luo and Brouwer, 2013) was used to display
annotated KEGG graphs across groups of samples for each GO term or KEGG pathway (respectively) with a Benjamini-Hochberg
false-discovery rate adjusted p value less than or equal to 0.05.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are expressed as mean ± SEM unless stated otherwise. Comparisons between two groups were performed using an unpaired,
two- tailed t test. ANOVA was used for more than 2 groups. A p value less than 0.05 was considered significant. Statistical analysis
and graphs were generated using GraphPad Prism software.
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Figure S1. Effect of MED19 knockout on adipocyte gene expression and characterization of MED19-AKO mice. Related to Figure 1.
(A-G) Gene expression time course of adipogenic genes in MED19-iKO iWAT SVF cells; n=3 each. (H-I) Cell viability in control and MED19
knockdown iWAT SVF cells and C2C12 cells measured using WST1 assay reagent. (J) Body weight of control and MED19-AKO female mice
at 3 (n=3 Lox/Lox, 4 MED19-AKO), 6 (n=6 each), 9 (n=3 Lox/Lox, 4 MED19-AKO), and 12wk of age (n=3 Lox/Lox, 4 MED19-AKO). (K)
Food intake in MED19-AKO and control male mice; n=4 each. (L) Body composition analysis by EchoMRI of 12wk old male mice; n=7
Lox/Lox, 8 MED19-AKO (M) Body composition analysis by EchoMRI of 12wk old female mice; n=9 Lox/Lox, 7 MED19-AKO. (N) Tissue
weight of asWAT, rWAT, and mWAT of 12wk old male MED19-AKO mice; n=3 each. (O) Adipose tissue weights of 3wk old male MED19-
AKO mice; n=4 Lox/Lox, 3 MED19-AKO. (P) qPCR analysis of gene expression in iWAT of MED19-AKO and control mice; n=5 Lox/Lox, 7
MED19-AKO. *p < 0.05, **p < 0.005, ***p < 0.0005.
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Figure S2. Glucose tolerance test in female mice. Related to Figure 2. Glucose tolerance test in control and MED19-AKO female mice; n=4
Lox/Lox, 3 MED19-AKO. *p < 0.05.
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Figure S3. Effect of inducible adipose-specific MED19 KO on body weight and lipolysis. Related to Figure 3. (A) Body weight of
MED19-iAKO mice 21 days following TAM injections; n=5 each. (B) Lipolysis assay in iWAT tissue explants from control and MED19-iAKO
mice; n=4 each. (C) Expression of lipolysis genes was reduced in iWAT of MED19-iAKO mice; n=5 each. *p < 0.05, **p < 0.005, ***p <
0.0005.
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Figure S4. PPARγ and/or C/EBPα overexpression does not rescue adipogenesis in MED19 depleted cells. Related to Figure 4. (A) Gene
expression analysis in differentiated PPARγ2-MEFs overexpressing GFP or C/EBPα and treated with scrambled or MED19 shRNA; n=3 each.
(B) Oil red O staining of the cells in panel A. Scale bar=300µm. (C-D) Gene expression analysis before (C) and after (D) differentiation of
MED19-iKO cells overexpressing PPARγ and treated with vehicle or 4-hydroxy-tamoxifen to induce MED19 KO; n=2 each. (E) Oil red O
staining in the cells from panel D. Scale bar=300µm. (F) Gene expression analysis of MED19-iKO cells under the same conditions used in the
PLA assay in Figure 4J-K; n=3 each. *p < 0.05, **p < 0.005, ***p < 0.0005.
Target Fwd (5' to 3') Rev (3' to 5') Reference
L32 TTCCTGGTCCACAATGTCAA GGCTTTTCGGTTCTTAGAGGA This paper
Cidea CAGTGATTTAAGAGACGCGG TCTGCAATCCCATGAATGTC This paper
Med19 AGTGGCCCCTTCTACCTGAT TAGGCCTGCTCCAGGTTGTA This paper
aP2 GCGTGGAATTCGATGAAATCA CCCGCCATCTAGGGTTATGA This paper
C/EBP⍺ CCAAGAAGTCGGTGGACAAG TTGTTTGGCTTTATCTCGGC This paper
KLF5 AGCGACGTATCCACTTCTGC CAGGTGCACTTGTAGGGCTT This paper
Krox20 TTGACCAGATGAACGGAGTG CAGGTGCACTTGTAGGGCTT This paper
MyoD TACAGTGGCGACTCAGATGC GAGATGCGCTCCACTATGCT This paper
MyoG CTACAGGCCTTGCTCAGCTC ACGATGGACGTAAGGGAGTG This paper
Desmin GTGGATGCAGCCACTCTAGC TTAGCCGCGATGGTCTCATAC This paper
Myf5 CAGCCCCACCTCCAACTG GGGACCAGACAGGGCTGTTA This paper
CD36 GCGACATGATTAATGGCACA CCTGCAAATGTCAGAGGAAA This paper
PRDM16 CAGAGGTGTCATCCCAGGAG ACGGATGTACTTGAGCCAGC This paper
Pgc-1⍺ TGTAGCGACCAATCGGAAAT TGAGGACCGCTAGCAAGTTT This paper
Ebf2 GCTGCGGGAACCGGAACGAGA ACACGACCTGGAACCGCCTCA This paper
Lipe ACGCTACACAAAGGCTGCTT TCTCGTTGCGTTTGTAGTGC This paper
Agpat2 GAGCCTTCTACTTGGCCATCCA TTGATTGTTCCTGAGGTGAAGAGCThis paper
Retn AAGAACCTTTCATTTCCCCTCCTGTCCAGCAATTTAAGCCAATGTT This paper
ATGL CCAACGCCACTCACATCTAC GCCTCCTTGGACACCTCAAT This paper
Abdh5 TGGTGTCCCACATCTACATCA CAGCGTCCATATTCTGTTTCCA This paper
FABP4-PPRE AA TGTCAGGCA TCTGGGAAC GACAAAGGCAGAAA TGCACA Lefterova et al., 2010
CD36 PPRE CCAACGGAACTGA TTTGAGC TTGCTGCTACACTCCAGCAT Lefterova et al., 2010
Retn-ChIP AGATTCTATTGAGTCATTCACACAAGGGGCCTGTCCCTTTGGA Rajakumari et al., 2013
Lipe-ChIP TGGGTCATAGTTGGCTAGGG CAGTGGGGACATGGTAAGT Rajakumari et al., 2013
Agpat2-PPRE AGTCCTCAGACCACCTGACC TCCAGTCCTGTCCTTCTCCA Villanueva et al., 2011
Supplemental Table 1: Oligonucleotide sequences. Related to STAR Methods.
